Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Abstract: The present invention is directed to a kit-of-parts for bleaching keratin fibers, having a bleaching composition A comprising a) one or more persalt(s) and/or peroxy salt(s), and b) one or more alkalizing agent(s), an aqueous oxidizing composition B, and a composition C comprising c) one or more non-acetylated sugar alcohol(s), and/or their mixtures, wherein the bleaching composition A comprises less than 5% by weight of water, calculated to the total weight of the bleaching composition A.

Abstract: The present invention relates to a composition for feeding a ruminant comprising i) a non-protein nitrogen compound, and ii) a coating surrounding the non-protein nitrogen compound, wherein said coating comprises one or more layers of a mixture of a saturated fat and a fatty acid, and said coating comprises from 60 wt.-%+/?10% to 85 wt.-%+/?10% of the saturated fat, e.g. hydrogenated fat, and from 15 wt.-%+/?10% to 40 wt.-%+/?10% of the fatty acid, each based on the total weight of the coating; a process for the preparation of said composition and its uses, e.g., for improving nitrogen utilization in a ruminant.

Abstract: The present invention relates to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.

Abstract: An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.

Abstract: The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.

Abstract: The present disclosure provides chewable tablets comprising (i) a compressed core including a bioactive molecule; (ii) a protective layer over said compressed core, and (iii) one or more soft-coating layers over said protective layer, each soft coating layer comprises gum base powder; wherein the protective layer comprises water-insoluble cellulose based polymers, preferably ethyl cellulose based polymer.

Abstract: The present invention relates to drug delivery vehicles comprising micronized particles that include an active lipid agent, and in particular to micronized lipid particles that comprise an ether lipid such as sn-1-O-eicosanyl-sn-2-palmitoyl-glycerol and its isomers.

Abstract: The present invention relates to drug delivery vehicles comprising micronized particles that include an active lipid agent, and in particular to micronized lipid particles that comprise an ether lipid such as sn-1-O-eicosanyl-sn-2-palmitoyl-glycerol and its isomers.

Abstract: An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.

Abstract: Disclosed is a method of improving the appearance of skin with a low-pH skin care composition that contains hydroxycinnamic acid (HCA) and a vitamin B3 compound in a synergistic combination.

Abstract: The present disclosure is directed to providing a moldable solid washing agent composition and an article molded from the same. The composition of the present disclosure can be stored easily at room temperature for a long time. It is applicable to a system that can be manufactured on site and can satisfy customer needs because it can be molded immediately by a simple method and the shape, size, etc. can be controlled. In addition, the solid washing agent composition disclosed in the present specification has superior compatibility with water.

Abstract: The invention relates to lipophilic transport particles for cosmetic or pharmaceutical active ingredients. The lipophilic transport particles comprise polyglycerol fatty acid ester as a main constituent and, because of the absence of polymorphic transformations, even during long storage, neither have volume changes nor allow the problem of expulsion of the adhering or enclosed active ingredient, due to intense structuring of the crystal lattice and associated compaction, to arise, and therefore the degree of loading with active ingredient and the release profile are stable.

Abstract: Compositions suitable for use as biodegradable coatings, comprising mixtures of naturally sourced waxes and naturally sourced crosslinkable agents. Compositions may be used to impart water resistance to a substrate, to control the release time of soil nutrients, to reduce environmental damage, and to protect seed or crop damage from high local concentrations of salts. Compositions are preferably prepared as aliphatic alcohol and thereafter may be disposed about an agronomically important substrate core or a fibrous substrate, at temperatures below about 90° C. to impart water resistance or extend the storage time.

Abstract: Improved spherical beads that may be used in producing pharmaceutically active pellets by depositing a pharmaceutically active agent on the surface of said spherical beads. The spherical beads includes a pharmaceutically acceptable carrier material, including: a) at least 60 wt. % of phosphoric acid calcium salt and b) up to 40 wt. % of organic material. Greater than or equal to 90 wt % of the spherical beads have a particle size in the range of from 90 ?m to 1200 ?m. The spherical beads have: a bulk density of at least or more than 1000 g/l, a specific surface area of at most or less than 10 m2/g, and a hardness of at least or more than 600 g/mm2. Also included is a method for producing such spherical beads and to pharmaceutically active pellets being prepared by depositing a pharmaceutically active agent on the surface of the spherical beads.

Abstract: The invention relates to stable liquid compositions comprising cyclohexanedione oxime herbicides (preferably clethodim), a water miscible solvent (preferably alkyl benzene), and at least one non-ionic surfactant (preferably mixture of lower HLB surfactant with higher HLB surfactant, or alternatively mixture of high HLB surfactants and fluroxypyr meptyl) and uses thereof.

Abstract: The present disclosure provides an arctigenin liquid nano-preparation and a preparation method thereof, and relates to the technical field of pharmaceutical preparation. In the present disclosure, arctigenin is prepared into a liquid nano-preparation, having advantages of distribution of a droplet diameter on nanoscale, significantly increased specific surface area, rapid absorption, and high bioavailability. Meanwhile, nano-preparation entered the body can be captured by wandering leucocytes, and a medicament is delivered to inflammatory lesions through chemiotaxis, thereby conferring a targeted drug delivery feature on the arctigenin and making a therapy more targeted.

Abstract: In the instant disclosure relates to a leave-on hair treatment composition and to methods for treating hair using the hair treatment composition. The hair treatment composition include: (a) water; (b) about 5 to about 40 wt. % of one or more polyols chosen from glycerin, ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, pentylene glycol, diethylene glycol, dipropylene glycol, 1,3 propanediol, and a mixture thereof; (c) at least 20 wt. % of one or more oils; and (d) at least 0.5% of one or more C1-C9 non-polymeric and non-thiol, mono-, di-, and/or tri-carboxylic acids; and the ratio of ((a)+(b)) to (c) is about 1:1 to about 1:5. The composition imparts durability, hydration, and moisturization to hair in addition to desirable styling effects.

Abstract: Synthesis of a compound N-(pyrimidin-2-ylcarbamothioyl) benzamide and its use as an insecticidal agent.

Abstract: The invention discloses a treatment composition to treat nasal or oral dryness and allergy symptoms, and a method for using the same. Certain compositions include xylitol, at least two wetting agents, an aqueous carrier, and other active ingredients, such as a potassium salt, a sodium salt, and a preservative. The composition may be configured as a nasal or oral spray, and oral rinse, or a nasal gel.